ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,303.27
0.12%
Dow Jones
40,003.59
0.34%
US Dollar vs MXN
16.6086
0.00%
Brent Oil
83.76
0.00%
Bitcoin
66,983.19
-0.15%
Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NYSE
  6. Bristol Myers Squibb Co (BMY)

  7. Bristol Myers Squibb Co (BMY) Noticias

BMY

Bristol Myers Squibb (BMY)

Bristol Myers Squibb Co
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NYSE:BMY
FechaHoraFuenteTítuloSímboloCompañía
16/05/202409:26Business WireNew Four-Year Sotyktu (deucravacitinib) Data Demonstrate Durable Response Rates and Consistent Safety in Moderate-to-Severe Plaque PsoriasisNYSE:BMYBristol Myers Squibb Co
15/05/202419:57Business WireBristol Myers Squibb’s CAR T Cell Therapy Breyanzi Approved by the U.S. Food and Drug Administration for Relapsed or Refractory Follicular LymphomaNYSE:BMYBristol Myers Squibb Co
13/05/202406:16IH Market NewsArm Sets 2025 Target for AI Chip Development, Amazon and Microsoft Commit Billions to French Investments, and MoreNYSE:BMYBristol Myers Squibb Co
10/05/202415:30Business WireBristol Myers Squibb Provides Update on Phase 3 CheckMate -73L TrialNYSE:BMYBristol Myers Squibb Co
07/05/202405:59Business WireBristol Myers Squibb to Participate in Upcoming Investor ConferencesNYSE:BMYBristol Myers Squibb Co
06/05/202405:59Business WireU.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Application for Subcutaneous Nivolumab (nivolumab and hyaluronidase)NYSE:BMYBristol Myers Squibb Co
06/05/202405:59Business WireEuropean Medicines Agency Validates Bristol Myers Squibb’s Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite...NYSE:BMYBristol Myers Squibb Co
01/05/202407:00GlobeNewswire Inc.Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell CollaborationNYSE:BMYBristol Myers Squibb Co
29/04/202405:00PR Newswire (US)Repertoire® Immune Medicines and Bristol Myers Squibb Announce Multi-Year Strategic Collaboration to Develop Tolerizing Vaccines for Autoimmune DiseasesNYSE:BMYBristol Myers Squibb Co
26/04/202405:59Business WireCHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb’s Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial CarcinomaNYSE:BMYBristol Myers Squibb Co
25/04/202406:53IH Market NewsU.S. Futures Drop in Pre-Market Trading as Tech Stocks Plunge After Meta Issues Gloomy ForecastNYSE:BMYBristol Myers Squibb Co
25/04/202405:59Business WireBristol Myers Squibb Reports First Quarter Financial Results for 2024NYSE:BMYBristol Myers Squibb Co
23/04/202406:25IH Market NewsApple Loses Market Share in China, GM Surges in Pre-Market Following Upward Revisions for 2024 Projections, and More NewsNYSE:BMYBristol Myers Squibb Co
22/04/202405:59Business WireBristol Myers Squibb and Cellares Announce a $380M Worldwide Capacity Reservation and Supply Agreement for the Manufacture of CAR T Cell Therapies to Bring the Promise of Cell Therapy to More Patients, FasterNYSE:BMYBristol Myers Squibb Co
08/04/202410:30Business WireKRAZATI (adagrasib) in Combination with Cetuximab Demonstrates Clinically Meaningful Activity as a Targeted Treatment Option for Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)NYSE:BMYBristol Myers Squibb Co
06/04/202412:15Business WireBristol Myers Squibb Presents New Interim Long-Term Efficacy Data from the EMERGENT-4 Trial Evaluating KarXT in Schizophrenia at the 2024 Annual Congress of the Schizophrenia International Research SocietyNYSE:BMYBristol Myers Squibb Co
06/04/202412:15Business Wire Bristol Myers Squibb Presents New Pooled Interim Long-Term Safety and Metabolic Outcomes Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the 2024 Annual Congress of the Schizophrenia International Research SocietyNYSE:BMYBristol Myers Squibb Co
05/04/202408:05Business WireU.S. FDA Approves Bristol Myers Squibb and 2seventy bio’s Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of TherapyNYSE:BMYBristol Myers Squibb Co
02/04/202419:08Business WireEuropean Commission Expands Approval of Bristol Myers Squibb’s Reblozyl® (luspatercept) to Include First-Line Treatment of Transfusion-Dependent Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (LR-MDS)NYSE:BMYBristol Myers Squibb Co
02/04/202405:59Business WireBristol Myers Squibb Releases 2023 Environmental, Social and Governance Report Demonstrating Progress and Setting New Long-Term GoalsNYSE:BMYBristol Myers Squibb Co
28/03/202415:05Business WireBristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung…NYSE:BMYBristol Myers Squibb Co
28/03/202415:01Business WireBristol Myers Squibb Provides Update on the First Phase 3 YELLOWSTONE Trial Evaluating Oral Zeposia (ozanimod) in Patients with Moderate to Severe Active Crohn’s DiseaseNYSE:BMYBristol Myers Squibb Co
28/03/202406:30GlobeNewswire Inc.Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Year 2023 Financial ResultsNYSE:BMYBristol Myers Squibb Co
26/03/202413:25Business WireA Bristol Myers Squibb Expande as Iniciativas de Doações para a Equidade em Saúde a fim de Melhorar os Resultados de SaúdeNYSE:BMYBristol Myers Squibb Co
26/03/202405:59Business WireBristol Myers Squibb Expands Health Equity Grant Initiatives to Improve Health OutcomesNYSE:BMYBristol Myers Squibb Co
25/03/202407:00Business WireBristol Myers Squibb to Present Data at the American College of Cardiology Annual Scientific Session 2024 Reinforcing Extensive Body of Evidence in Clinical and Real-World Settings Across Cardiovascular PortfolioNYSE:BMYBristol Myers Squibb Co
20/03/202415:45Business WireBristol Myers Squibb’s Abecma (idecabtagene vicleucel) Becomes First CAR T Cell Therapy Approved in the European Union in Earlier Lines for Triple-Class Exposed Relapsed and Refractory Multiple MyelomaNYSE:BMYBristol Myers Squibb Co
20/03/202405:59Business WireBristol Myers Squibb Announces CheckMate -9DW Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) Meets Primary Endpoint of Overall Survival for the First-Line Treatment of Advanced Hepatocellular CarcinomaNYSE:BMYBristol Myers Squibb Co
19/03/202405:59Business WireBristol Myers Squibb and Ted Danson Empower Those with Plaque Psoriasis to Take Action in “SO, Have You Found It?” CampaignNYSE:BMYBristol Myers Squibb Co
18/03/202407:44Business WireBristol Myers Squibb Completes Acquisition of Karuna Therapeutics, Strengthening Neuroscience PortfolioNYSE:BMYBristol Myers Squibb Co
 Showing the most relevant articles for your search:NYSE:BMY

Su Consulta Reciente

TSX
FVL
Freegold Ventures
AMEX
HWK
Hawk
LSE
ERM
Euromoney Institutional ...
NASDAQ
BRIL
NASDAQ
ABBCBXX
Hsbc Bank Usa Na Capped ...
USOTC
BLTMF
Blue Thunder Mining (PK)
TSXV
GON
NASDAQ
CAAADX
International Growth Fun...
NASDAQ
SKIS
Peak Resorts
AMEX
NRGO
Microsectors US Big Oil ...
NYSE
ESE
ESCO Technologies
USOTC
CBAF
CITBA Financial (QX)
OKEX
MDTETH
BOV
CSNAL137
CSNAL137 Ex:11,19
USOTC
BRCOF
Buscando Resources (PK)
LSE
LUP
Lupus Capital
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados